EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Early Toxicities of CAR-T Cell Therapy: Mechanisms, Prediction, and Management

Swathi Srikantan, Alexander Weiss, Zainab Muslehuddin, Shatha Farhan iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27219587 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Swathi Srikantan und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Wayne State University, Detroit, MI 48201, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Cytokine Release Syndrome, Receptors, Chimeric Antigen. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T (CAR-T) cell therapy has completely reshaped the therapeutic landscape for some blood cancers, including B-cell lymphoma, myeloma, and acute lymphoblastic leukemia. However, the complications associated with this powerful therapy are preventing it from being used more widely. This review explores the underlying biology, clinical signs, and current treatments for the three major early CAR-T cell therapy-associated toxicities: cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Here, we outline key findings from preclinical animal models, data from multicenter clinical trials, and real-world patient cohort study data to delineate how infused cells and different host-derived and blood–brain barrier disruptions contribute to these adverse effects. A growing body of evidence is revealing that the patient’s own monocytes and macrophages, not just the infused CAR-T cells, may contribute to driving systemic toxicities primarily by releasing interleukin-1 (IL-1) and IL-6. A more thorough and mechanistically detailed understanding of CAR-T cell therapy-associated toxicity is needed to develop better predictive tools and treatment strategies so that patients derive the greatest antitumor benefits with the lowest risk of severe treatment-related complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveCytokine Release SyndromeReceptors, Chimeric AntigenHumansAnimalsLymphohistiocytosis, HemophagocyticNeurotoxicity Syndromes

Stichwörter der Autor:innen

CAR-T cell therapyanakinracytokine release syndromeimmune effector cell-associated hemophagocytic lymphohistiocytosis-like syndromeimmune effector cell-associated neurotoxicity syndromemacrophage activationneuroinflammationpredictive biomarkerstocilizumab

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • School of Medicine, Wayne State University, Detroit, MI 48201, USA.
  • Hematology Oncology, Henry Ford Health, Detroit, MI 48236, USA.
  • Stem Cell Transplant and Cell Therapy, Henry Ford Health, Detroit, MI 48202, USA.

ORCID-Profile: Shatha Farhan

Zitieren

APA

Srikantan, S., Weiss, A., Muslehuddin, Z., & Farhan, S. (2026). Early Toxicities of CAR-T Cell Therapy: Mechanisms, Prediction, and Management. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27219587

Vancouver

Srikantan S, Weiss A, Muslehuddin Z, Farhan S. Early Toxicities of CAR-T Cell Therapy: Mechanisms, Prediction, and Management. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27219587

BibTeX
@article{Srikantan2026,
  author = {Srikantan, Swathi and Weiss, Alexander and Muslehuddin, Zainab and Farhan, Shatha},
  title = {Early Toxicities of CAR-T Cell Therapy: Mechanisms, Prediction, and Management},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27219587}
}
Kostenlos starten →